In the afternoon of March 11, 2008, the organic institute launched the opening ceremony of the "GlaxoSmithKline Graduate Education Fund". The ceremony was attended by the director of organic institute Researcher Biao Jiang, deputy party secretary of Researchers Kuiling Ding, tutor and graduate students of the institute. Dr. Jingwu Zang, president of the GlaxoSmithKline R & D center in China and the persons who in charge of Ministry of Personnel of R & D Center, biotechnology, chemical and technology platform and other departments attended the ceremony.

The activities preside over by Researcher Kuiling Ding. Biao Jiang, director of the institute first speech to thank GlaxoSmithKline R & D center in China to set up post-graduate fund to support the graduate students in organic institute to effort in scientific exploration and hope the next two academic would carry out exchanges, science and technology cooperation in the multi-faceted cooperation, meet national needs, and promote new drug research and development of China's pharmaceutical business. Subsequently, President of GlaxoSmithKline R & D center in China, Dr. Jingwu Zang introduce the intention of setting up the fund. It aimed at building a platform and promoting the growth of young researchers through educating, training and researching work supported by the fund. Dr. Zhang also detailed descriptions of the blueprint for future development and personnel recruitment and training plan of GlaxoSmithKline R & D center in China's

GlaxoSmithKline is the world's largest, research and development-based multi-national pharmaceutical companies. By in merger of two major pharmaceutical companies Glaxo Welcome and SmithKline Beecham in December 2000, with headquarters in the United Kingdom, the business operations center in the United States, having 85 production bases in 37 countries, the company had a total of more than 100,000 employees. The company had the largest global pharmaceutical industry, research and development system, and has established 24 R & D centers in 11 countries, having over 15,000 R & D personnel and more than 5 billion U.S. dollars R & D expenses, at the leading status in the Gene / genetics research in world. Glaxo is currently engaged in the world's only World Health Organization to deal with the three major diseases - AIDS, tuberculosis, malaria research pharmaceutical companies, and the products are mainly covered by asthma, anti-virus, infectious disease, diabetes and central nervous system and digestive tract, in these six major disease areas and also the world's leading vaccine development and production business.

GlaxoSmithKline R & D center in China will be responsible for all research and development of new drugs, including from the search for new drug targets, to basic research, chemical synthesis, clinical research, and even to produce registration. China's R & D center will focus on neurodegenerative disease research. The goal is to develop new drugs for multiple sclerosis, Parkinson's disease and Alzheimer's disease and other serious diseases. Glaxo will lead the center in this field of research and development activities worldwide, and carry out close cooperation with other research institutions, and become a team leader in the "China-chi made" road

After the opening ceremony activities, GlaxoSmithKline R & D centers in China were also conducted with graduate students to understand interaction.

Administration Office